Multi-drug-resistant tuberculosis classification: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
(Created page with "__NOTOC__ {{Multi-drug-resistant tuberculosis}} Please help WikiDoc by adding content here. It's easy! Click here to learn about editing. ==Ref...")
 
m (Changes made per Mahshid's request)
 
(12 intermediate revisions by 3 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Multi-drug-resistant tuberculosis}}
{{Multi-drug-resistant tuberculosis}}
Please help WikiDoc by adding content here. It's easy! Click  [[Help:How_to_Edit_a_Page|here]] to learn about editing.
{{CMG}} ; {{AE}} {{Ammu}}
==Overview==
Classification of drug resistant tuberculosis is based on drug susceptibility , pathophysiology, clinical classification and molecular classification. According to drug susceptibility it is classified as monoresistance, poly resistance, multidrug resistance, extensive drug resistance and [[rifampicin]] resistance. Clinically it is classified as acquired and [[primary resistance]]. The [[restriction fragment length polymorphism]] helps for molecular classification into unique and cluster type.
 
==Classification==
Based on the drug susceptibility testing of cinical isolates confirmed to be [[Mycobacterium tuberculosis]],
the strains are classified as follows. <ref name=WHO>{{cite web | title =Drug resistance Classification| url =http://apps.who.int/iris/bitstream/10665/79199/1/9789241505345_eng.pdf }}</ref>
{| style="border: 0px; font-size: 90%; margin: 3px; width: 700px" align=center
|valign=top|
|+
! style="background: #4479BA; width: 250px;" | {{fontcolor|#FFF|Classification}}
! style="background: #4479BA; width: 350px;" | {{fontcolor|#FFF|Description}}
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Monoresistance
| style="padding: 5px 5px; background: #F5F5F5;" |Strain resistant to any one of the first line anti tubercular drugs
|-
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |[[Polydrug resistance]]
| style="padding: 5px 5px; background: #F5F5F5;" |Strain resistant to more than one first line anti tubercular drugs. (Other than both [[rifampicin]] and [[isoniazid]])
|-
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |Multidrug resistance
| style="padding: 5px 5px; background: #F5F5F5;" |Strain resistant to both [[rifampicin]] and [[isoniazid]]
|-
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |Extensive drug resistance
| style="padding: 5px 5px; background: #F5F5F5;" |In addition to the multi drug resistance, strain is resistant to any [[fluroquinolone]] and to atleast one of the three second line injectable anti [[TB]] drugs like [[amikacin]], [[capreomycin]] and [[kanamycin]].
|-
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |[[Rifampicin]] resistance
| style="padding: 5px 5px; background: #F5F5F5;" | Using genotypic or phenotypic method, strain has been detected to have resistance to [[rifampicin]] with or without resistance to other anti [[TB]] drugs. It can include monoresistance, multi drug resistance, poly drug resistance or extensive drug resistance.
|}
 
===Clinical classification===
Clinically drug resistant tuberculosis can be classified into acquired drug resistance and primary drug resistance according to pathophysiology.<ref name="pmid10892760">{{cite journal| author=Van Rie A, Warren R, Richardson M, Gie RP, Enarson DA, Beyers N et al.| title=Classification of drug-resistant tuberculosis in an epidemic area. | journal=Lancet | year= 2000 | volume= 356 | issue= 9223 | pages= 22-5 | pmid=10892760 | doi=10.1016/S0140-6736(00)02429-6 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10892760  }} </ref>
 
====Acquired resistance====
According to WHO , acquired resistance is defined  as the isolation of drug resistant M. tuberculosis from a patient who has been treated for TB for one month or longer.
Strains can acquire resistance against anti tubercular drugs in the following conditions.
*Inadequately treated by errors by caregivers in prescribing or administering drugs or supplying a poor quality drug
*Patients not completing the full course of treatment
*Patient receiving only partial treatment.
Such conditions can lead to the bacterial population to live for several months during the course of treatment thereby developing resistance against such drugs.
 
====Primary resistance====
WHO defines primary resistanc as the isolation of a drug resistant strain from a patient without a history of previous treatment.
When a patient gets infected with strains already resistant to anti tubercular drugs it is called as primary resistance. It could be against one drug of 1st line anti tubercular drugs or many drugs in the first and second line of drugs.
 
===Molecular classification===
====Unique====
The restriction fragment length polymorphism helps in molecular classification of drug resistance into unique strains of drug resistance.
 
====Cluster====
The restriction fragment length polymorphism helps in molecular classification of drug resistance into cluster of strains of drug resistance.
 
====Classification based on pathogenesis====
 
Below is a table with the current classification system of [[tuberculosis]] ([[TB]]), based on its [[pathogenesis]]:<ref name=CDC>{{cite web | title = TB Classification | url = http://www.cdc.gov/tb/publications/slidesets/selfstudymodules/module1/classification.htm }}</ref>
{| style="border: 0px; font-size: 90%; margin: 3px;" align=center
|valign=top|
|+
! style="background: #4479BA; width: 50px;" | {{fontcolor|#FFF|Class}}
! style="background: #4479BA; width: 250px;" | {{fontcolor|#FFF|Type of Tuberculosis}}
! style="background: #4479BA; width: 250px;" | {{fontcolor|#FFF|Description}}
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |
0
| style="padding: 5px 5px; background: #F5F5F5;" |
No [[TB]] exposure<br>
Not infected
| style="padding: 5px 5px; background: #F5F5F5;" |
No history of [[TB]] exposure<br>
Negative result to a [[TST]] or [[IGRA]]
|-
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |
1
| style="padding: 5px 5px; background: #F5F5F5;" |
[[TB]] exposure<br>
No evidence of [[infection]]
| style="padding: 5px 5px; background: #F5F5F5;" |
History of [[TB]] exposure<br>
Negative result to a [[TST]] (given at least 8-10 weeks after exposure) or [[IGRA]]
|-
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |
2
| style="padding: 5px 5px; background: #F5F5F5;" |
[[TB]] infection<br>
No [[TB]] disease   
| style="padding: 5px 5px; background: #F5F5F5;" |
Positive result to a [[TST]] or [[IGRA]]<br>
Negative smears and cultures (if done)<br>
No clinical or [[x-ray]] evidence of active [[TB]] disease
|-
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |
3
| style="padding: 5px 5px; background: #F5F5F5;" |
Clinically active [[TB]]
| style="padding: 5px 5px; background: #F5F5F5;" |
Positive culture (if done) for ''[[M. tuberculosis]]''<br>
Positive result to a [[TST]] or [[IGRA]], and clinical, bacteriological, or [[x-ray]] evidence of [[TB]] disease
|-
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |
4
| style="padding: 5px 5px; background: #F5F5F5;" |
Previous [[TB]] disease (not clinically active)
| style="padding: 5px 5px; background: #F5F5F5;" |
Medical history of [[TB]] disease<br>
Abnormal but stable [[x-ray]] findings<br>
Positive result to a [[TST]] or [[IGRA]]<br>
Negative smears and cultures (if done)<br>
No clinical or [[x-ray]] evidence of active [[TB]] disease
|-
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |
5
| style="padding: 5px 5px; background: #F5F5F5;" |
Suspected [[TB]]
| style="padding: 5px 5px; background: #F5F5F5;" |
[[Signs]] and [[symptoms]] of [[TB]] disease, but incomplete evaluation
|-
|}
 
==References==
==References==
{{reflist|2}}
{{reflist|2}}
{{WH}}
{{WH}}
{{WS}}
[[Category:Disease]]
[[Category:Bacterial diseases]]
[[Category:Pulmonology]]
[[Category:Tuberculosis| ]]

Latest revision as of 18:06, 18 September 2017


Multi-drug-resistant tuberculosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Multi-drug-resistant tuberculosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Multi-drug-resistant tuberculosis classification On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Multi-drug-resistant tuberculosis classification

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Multi-drug-resistant tuberculosis classification

CDC on Multi-drug-resistant tuberculosis classification

Multi-drug-resistant tuberculosis classification in the news

Blogs on Multi-drug-resistant tuberculosis classification

Directions to Hospitals Treating Multi-drug-resistant tuberculosis

Risk calculators and risk factors for Multi-drug-resistant tuberculosis classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Overview

Classification of drug resistant tuberculosis is based on drug susceptibility , pathophysiology, clinical classification and molecular classification. According to drug susceptibility it is classified as monoresistance, poly resistance, multidrug resistance, extensive drug resistance and rifampicin resistance. Clinically it is classified as acquired and primary resistance. The restriction fragment length polymorphism helps for molecular classification into unique and cluster type.

Classification

Based on the drug susceptibility testing of cinical isolates confirmed to be Mycobacterium tuberculosis, the strains are classified as follows. [1]

Classification Description
Monoresistance Strain resistant to any one of the first line anti tubercular drugs
Polydrug resistance Strain resistant to more than one first line anti tubercular drugs. (Other than both rifampicin and isoniazid)
Multidrug resistance Strain resistant to both rifampicin and isoniazid
Extensive drug resistance In addition to the multi drug resistance, strain is resistant to any fluroquinolone and to atleast one of the three second line injectable anti TB drugs like amikacin, capreomycin and kanamycin.
Rifampicin resistance Using genotypic or phenotypic method, strain has been detected to have resistance to rifampicin with or without resistance to other anti TB drugs. It can include monoresistance, multi drug resistance, poly drug resistance or extensive drug resistance.

Clinical classification

Clinically drug resistant tuberculosis can be classified into acquired drug resistance and primary drug resistance according to pathophysiology.[2]

Acquired resistance

According to WHO , acquired resistance is defined as the isolation of drug resistant M. tuberculosis from a patient who has been treated for TB for one month or longer. Strains can acquire resistance against anti tubercular drugs in the following conditions.

  • Inadequately treated by errors by caregivers in prescribing or administering drugs or supplying a poor quality drug
  • Patients not completing the full course of treatment
  • Patient receiving only partial treatment.

Such conditions can lead to the bacterial population to live for several months during the course of treatment thereby developing resistance against such drugs.

Primary resistance

WHO defines primary resistanc as the isolation of a drug resistant strain from a patient without a history of previous treatment. When a patient gets infected with strains already resistant to anti tubercular drugs it is called as primary resistance. It could be against one drug of 1st line anti tubercular drugs or many drugs in the first and second line of drugs.

Molecular classification

Unique

The restriction fragment length polymorphism helps in molecular classification of drug resistance into unique strains of drug resistance.

Cluster

The restriction fragment length polymorphism helps in molecular classification of drug resistance into cluster of strains of drug resistance.

Classification based on pathogenesis

Below is a table with the current classification system of tuberculosis (TB), based on its pathogenesis:[3]

Class Type of Tuberculosis Description

0

No TB exposure
Not infected

No history of TB exposure
Negative result to a TST or IGRA

1

TB exposure
No evidence of infection

History of TB exposure
Negative result to a TST (given at least 8-10 weeks after exposure) or IGRA

2

TB infection
No TB disease

Positive result to a TST or IGRA
Negative smears and cultures (if done)
No clinical or x-ray evidence of active TB disease

3

Clinically active TB

Positive culture (if done) for M. tuberculosis
Positive result to a TST or IGRA, and clinical, bacteriological, or x-ray evidence of TB disease

4

Previous TB disease (not clinically active)

Medical history of TB disease
Abnormal but stable x-ray findings
Positive result to a TST or IGRA
Negative smears and cultures (if done)
No clinical or x-ray evidence of active TB disease

5

Suspected TB

Signs and symptoms of TB disease, but incomplete evaluation

References

  1. ↑ "Drug resistance Classification" (PDF).
  2. ↑ Van Rie A, Warren R, Richardson M, Gie RP, Enarson DA, Beyers N; et al. (2000). "Classification of drug-resistant tuberculosis in an epidemic area". Lancet. 356 (9223): 22–5. doi:10.1016/S0140-6736(00)02429-6. PMID 10892760.
  3. ↑ "TB Classification".

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Multi-drug-resistant_tuberculosis_classification&oldid=1357534"